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Objectives 
ANCA associated vasculitis is complicated by frequent disease relapses. However, a 
proportion of patients have re-established immunological tolerance, demonstrating 
sustained clinical and immunological remission, off therapy. We studied these patients to 
define a tolerant phenotype. 
Methods 
Patients at 6 international centres were identified as tolerant from clinic databases and 
records examined. Patients who became ANCA negative following treatment, and remained 
ANCA negative in remission and off immunosuppresive (IS) therapy for 2 years or more were 
defined as tolerant(TOL). Those with recent relapses were termed non-tolerant(NON-TOL). 
A subset of TOL patients were compared to NON-TOL, age matched healthy control(HC)s 
and patients prior to and following drug withdrawal(DW) to identify a tolerance signature. 
Results 
48 tolerant patients were identified. Baseline characteristics are in Table 1. Induction 
regimens included steroids (92% patients) and cyclophosphamide (88%). During 
maintenance, 67% received azathioprine. Only 14% had episodes of relapse (none > 1) prior 
to becoming TOL. Median time to ANCA negativity was 6 months and was similar in PR3-and 
MPO-ANCA (5 and 8 months respectively;p=0.50). The proportion ANCA negative at 6 
months was similar to patients in the IMPROVE trial (P=0.67). Median time to stop therapy 
was 32 months and did not differ according to ANCA type. Median duration of persistent 
ANCA negativity was 71 months and median duration off IS 60 months. Analysis of PBMC in 
a subset of TOL patients(n=6) demonstrated higher proportion of CD24+CD38+ Breg 
compared to NON-TOL patients(n=3), and similar levels to HC (n=9). Proportions of Treg did 
not differ. Analysis of gene expression within leukocyte subsets (n=6 for TOL, NON-TOL, HC 
and n=2 for DW) demonstrated significant changes following drug withdrawal, and 
excluding these genes, over 40  genes remained differentially expressed in TOL compared 
with NON-TOL within CD4 compartment, with ongoing analysis of CD8, CD14 and CD19 
subsets. 
Conclusions 
Reestablishment of tolerance occurs in both PR3- and MPO-ANCA subjects. TOL appear to 
have fewer relapses prior to IS withdrawal. Immunological differences are found between 
TOL and NON-TOL patients and these may allow a tolerance signature to be defined for 
customising therapy and use as end points in trial design.   
Table 1  
Tolerant patients   
Age current (median, range) 
Age at presentation (median, range) 
Gender  
ANCA subtype 
Time to ANCA negativity (median, range) 
Duration ANCA negative 
Relapse rate 
Time to stop IS from induction 
Time off IS since stopping 
69 (29-87)years 
57 (14-74) years 
50% female 
48% PR3-ANCA 
6 months (0.5-120) 
71 months (12-244) 
14% (none more than once) 
32 months (13-204) 
20 months (22-264) 
 
